LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 4.3% – What’s Next?

Posted by Brian Himes on Sep 3rd, 2026

LB Pharmaceuticals Inc (NASDAQ:LBRX – Get Free Report) shares traded down 4.3% during trading on Thursday . The stock traded as low as $47.22 and last traded at $47.3330. Approximately 93,780 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 267,904 shares. The stock had previously closed at $49.48.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on LBRX. Wolfe Research initiated coverage on LB Pharmaceuticals in a research report on Tuesday, July 7th. They set an “outperform” rating and a $45.00 price target on the stock. Roth Capital reiterated a “buy” rating and set a $37.00 target price on shares of LB Pharmaceuticals in a research note on Sunday, May 17th. BMO Capital Markets increased their target price on shares of LB Pharmaceuticals from $46.00 to $54.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Stifel Nicolaus set a $53.00 price target on shares of LB Pharmaceuticals in a research report on Thursday, August 13th. Finally, HC Wainwright boosted their price objective on shares of LB Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, LB Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $49.62.

Check Out Our Latest Stock Report on LBRX

LB Pharmaceuticals Stock Down 4.8%

The firm’s 50-day moving average price is $39.86 and its 200 day moving average price is $31.72. The firm has a market cap of $1.52 billion and a P/E ratio of -13.70.

LB Pharmaceuticals (NASDAQ:LBRX – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.87). On average, equities analysts predict that LB Pharmaceuticals Inc will post -5.16 earnings per share for the current year.

Institutional Trading of LB Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Spruce Street Capital LP acquired a new position in LB Pharmaceuticals during the 4th quarter worth $22,384,000. Stempoint Capital LP acquired a new position in shares of LB Pharmaceuticals during the first quarter valued at $1,233,000. Eversept Partners LP bought a new stake in shares of LB Pharmaceuticals during the first quarter valued at about $2,471,000. Janus Henderson Group PLC bought a new stake in shares of LB Pharmaceuticals during the first quarter valued at about $1,613,000. Finally, Great Lakes Advisors LLC acquired a new stake in LB Pharmaceuticals in the second quarter worth about $987,000.

LB Pharmaceuticals Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.